相关实验视频

Updated: Jun 27, 2025

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

试管婴儿刺激期间COVID-19疫苗接种对周期结果的影响 - 一个回顾性队列研究

Michal Youngster¹, Omer Maman², Alon Kedem¹

¹IVF Unit, Department of Obstetrics and Gynecology, Shamir Medical Center, Zerifin, Israel; IVF Unit, Herzliya Medical Centre, Herzliya, Israel; Sackler School of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Journal of reproductive immunology

|April 27, 2024

概括

在试管婴儿刺激期间接种COVID-19 mRNA-BNT162b2疫苗对卵细胞产量或怀孕率没有负面影响. 这一发现支持COVID-19疫苗用于生育治疗的安全性,在给药时间上提供了灵活性.

科学领域:

生殖医学生殖医学
疫苗学疫苗学疫苗学
在体外受精过程中受精.

背景情况:

之前的研究表明mRNA-BNT162b2疫苗在生育治疗之前的安全性.
在体外受精 (IVF) 刺激阶段接种疫苗的影响仍然未被描述.

研究的目的:

为了评估mRNA-BNT162b2疫苗在新鲜的试管婴儿周期中对周期结果的影响.
为了比较在刺激期间接种疫苗的患者,在刺激之前,和未接种疫苗的患者之间的结果.

主要方法:

对396名接受新鲜试管婴儿周期 (2021年1月至9月) 的患者进行了回顾性队列研究.
三个年龄相匹配的组:在刺激期间接种了132种疫苗,在刺激之前接种了132种疫苗,未接种了132种疫苗.
人口统计,周期特征,卵细胞产量,临床怀孕和正在进行的怀孕率的比较.

主要成果:

三组之间卵细胞产量没有显著差异 (9.35对10.22对10.05;p=0.491).
线性回归证实疫苗接种时间对卵细胞产量没有影响 (p>0.999).
临床怀孕率 (30% vs. 30% vs. 28%) 和正在进行的怀孕率 (所有组的25%) 在不同组中相似. 疫苗的注射和时间不是临床怀孕后勤回归的重要因素.

结论:

在试管婴儿刺激期间使用mRNA-BNT162b2疫苗不会对新鲜的试管婴儿治疗结果产生不利影响.
结果与刺激前接种疫苗的人和未接种疫苗的人相似.
这项研究为生育护理中的COVID-19疫苗安全性增加了证据,允许灵活的疫苗施用时间.

关键词:

在 COVID-19 疫情中,在这个过程中,IVF IVF.怀孕怀孕怀孕怀孕这就是SARS-CoV-2病毒.疫苗疫苗疫苗疫苗

更多相关视频

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

OP-IVM: Combining In vitro Maturation after Oocyte Retrieval with Gynecological Surgery

Published on: May 9, 2021

Modified MicroSecure Vitrification: A Safe, Simple and Highly Effective Cryopreservation Procedure for Human Blastocysts

Modified MicroSecure Vitrification: A Safe, Simple and Highly Effective Cryopreservation Procedure for Human Blastocysts

Published on: March 2, 2017

相关概念视频

In Vitro Fertilization

In Vitro Fertilization

In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...

Meiosis II

Meiosis II

Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...